CY1122441T1 - Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους - Google Patents

Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους

Info

Publication number
CY1122441T1
CY1122441T1 CY20191101166T CY191101166T CY1122441T1 CY 1122441 T1 CY1122441 T1 CY 1122441T1 CY 20191101166 T CY20191101166 T CY 20191101166T CY 191101166 T CY191101166 T CY 191101166T CY 1122441 T1 CY1122441 T1 CY 1122441T1
Authority
CY
Cyprus
Prior art keywords
therapeutic use
conjugations
preparation
cryptophycin compounds
novel cryptophycin
Prior art date
Application number
CY20191101166T
Other languages
Greek (el)
English (en)
Inventor
Antony Bigot
Hervé Bouchard
Marie-Priscille Brun
François CLERC
Jidong Zhang
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1122441T1 publication Critical patent/CY1122441T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Bedding Items (AREA)
CY20191101166T 2015-11-05 2019-11-06 Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους CY1122441T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (1)

Publication Number Publication Date
CY1122441T1 true CY1122441T1 (el) 2021-01-27

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101166T CY1122441T1 (el) 2015-11-05 2019-11-06 Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους

Country Status (35)

Country Link
US (2) US10941139B2 (enExample)
EP (1) EP3371179B1 (enExample)
JP (1) JP6929292B2 (enExample)
KR (1) KR102822076B1 (enExample)
CN (1) CN108349960B (enExample)
AR (1) AR106604A1 (enExample)
AU (1) AU2016347724B2 (enExample)
CA (1) CA3003085A1 (enExample)
CL (1) CL2018001210A1 (enExample)
CO (1) CO2018004581A2 (enExample)
CR (1) CR20180256A (enExample)
CY (1) CY1122441T1 (enExample)
DK (1) DK3371179T3 (enExample)
EA (1) EA035625B1 (enExample)
EC (1) ECSP18034035A (enExample)
ES (1) ES2755101T3 (enExample)
HK (1) HK1256754B (enExample)
HR (1) HRP20191729T1 (enExample)
HU (1) HUE046033T2 (enExample)
IL (1) IL259067B (enExample)
LT (1) LT3371179T (enExample)
MA (1) MA43160B1 (enExample)
MX (1) MX374535B (enExample)
MY (1) MY189448A (enExample)
PH (1) PH12018500852B1 (enExample)
PL (1) PL3371179T3 (enExample)
PT (1) PT3371179T (enExample)
RS (1) RS59498B1 (enExample)
SG (1) SG11201803181SA (enExample)
SI (1) SI3371179T1 (enExample)
TN (1) TN2018000131A1 (enExample)
TW (1) TWI714661B (enExample)
UY (1) UY36979A (enExample)
WO (1) WO2017076998A1 (enExample)
ZA (1) ZA201802322B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
MA50764A (fr) * 2017-05-10 2020-03-18 Sanofi Sa Linkers peptidiques et conjugués de cryptophycine, utiles en thérapie, et leur préparation
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
JP7645192B2 (ja) 2019-03-07 2025-03-13 ノボ メディシン インク. カスパーゼ阻害剤及びその使用方法
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (en) 2021-02-19 2022-08-24 Universität Bielefeld Cryptophycin compounds and conjugates thereof
CA3243937A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag PEPTIDE LINKS COMPRISING TWO OR MORE PAYLOADS
EP4495105A1 (en) 2023-07-17 2025-01-22 Basf Se 3-(4-hydroxybut-2-ynoxy)propanoic acid ester, amide and nitrile derivatives as corrosion protection agents
EP4495108A1 (en) 2023-07-17 2025-01-22 Basf Se 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy]propanoic acid derivatives as precursors of monomers in polymerisations
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695873B2 (en) * 1993-12-21 1998-08-27 University Of Hawaii New cryptophycins
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
CA3003085A1 (en) 2017-05-11
TWI714661B (zh) 2021-01-01
MA43160B1 (fr) 2019-12-31
AR106604A1 (es) 2018-01-31
HK1256754B (en) 2020-06-05
CO2018004581A2 (es) 2018-07-19
SI3371179T1 (sl) 2019-11-29
JP2018535255A (ja) 2018-11-29
TW201730164A (zh) 2017-09-01
CN108349960B (zh) 2022-05-27
CN108349960A (zh) 2018-07-31
DK3371179T3 (da) 2019-11-11
US10941139B2 (en) 2021-03-09
HUE046033T2 (hu) 2020-01-28
ES2755101T3 (es) 2020-04-21
ECSP18034035A (es) 2018-05-31
TN2018000131A1 (en) 2019-10-04
KR102822076B1 (ko) 2025-06-18
EP3371179A1 (en) 2018-09-12
AU2016347724B2 (en) 2021-04-01
US20190382391A1 (en) 2019-12-19
EA201890898A1 (ru) 2018-10-31
PH12018500852B1 (en) 2021-08-11
RS59498B1 (sr) 2019-12-31
SG11201803181SA (en) 2018-05-30
JP6929292B2 (ja) 2021-09-01
UY36979A (es) 2017-06-30
IL259067B (en) 2021-07-29
MX374535B (es) 2025-03-06
PH12018500852A1 (en) 2018-10-29
MX2018005379A (es) 2018-09-05
CL2018001210A1 (es) 2018-08-17
HRP20191729T1 (hr) 2019-12-13
PT3371179T (pt) 2019-11-18
PL3371179T3 (pl) 2020-02-28
KR20180073678A (ko) 2018-07-02
CR20180256A (es) 2018-08-13
EP3371179B1 (en) 2019-08-07
BR112018008490A2 (pt) 2019-02-12
US20210163458A1 (en) 2021-06-03
EA035625B1 (ru) 2020-07-17
IL259067A (en) 2018-06-28
ZA201802322B (en) 2019-01-30
LT3371179T (lt) 2019-11-11
NZ741734A (en) 2023-10-27
WO2017076998A1 (en) 2017-05-11
MY189448A (en) 2022-02-14
AU2016347724A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
EA201691940A1 (ru) Новые соединения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1119433T1 (el) Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
MX2017014035A (es) Formas solidas novedosas.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
DOP2017000034A (es) Compuestos de imidazopiridazina
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201790570A1 (ru) Модуляторы р2х7
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
CY1123394T1 (el) Φαρμακευτικη συνθεση
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof